fda compounding semaglutide news november 2025 Compound versions of GLP-1 drugs for weight loss halted by The FDA has received reports

Causality between inflammatory bowel disease and the cerebral cortex: insights from Mendelian randomization and integrated bioinformatics analysis

Two rules I tell every patient

Of the older therapies, sulphonylureas, insulin and glitazones are all associated with significant weight gain, whereas metformin is associated with slight weight loss

Avoid any website that does not disclose the name and licensing details of their pharmacy partners

Reintroduce it once you've stabilised at therapeutic dose

The nasal spray format ensures rapid absorption through the nasal mucosa, allowing noticeable effects shortly after use